The Pre-EUA is a first step in seeking formal authorization of Xlear Nasal Spray as tool to help in combatting COVID-19.
Xlear previously filed a pre-EUA seeking approval for use of the nasal spray as a medical device in combatting COVID-19.
However, because the FDA determined that Xlear "works against the virus," the FDA told Xlear it would need to be considered as a drug or combination product EUA.
Xlear's Pre-EUA Request is based on recent studies showing the nasal spray is virucidal (it kills the virus); antiviral (it blocks the adhesion of the virus to the nasal membrane, which is how most people get sick from COVID-19); antibacterial against streptococcus bacteria, which is the leading cause of bacterial pneumonia (a COVID-19 complication linked to morbidity); and, reduces both the duration and severity of illness when used to treat COVID-19 patients.
Xlear is currently sold in over 50,000 pharmacies, grocery stores, and online as a nasal spray.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon